Navigation Links
VIVUS to Present at the Deutsche Bank BioFEST Conference
Date:12/1/2011

rospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2010, and periodic reports filed with the Securities and Exchange Commission.CONTACT: 

 VIVUS, Inc.Investor Relations:The Trout Group Timothy E. Morris 

Brian KorbChief Financial Officer 

 

bkorb@troutgroup.com650-934-52 

646-378-2923
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VIVUS Reports Third Quarter and First Nine Months 2011 Financial Results
2. VIVUS to Present at the BioCentury NewsMakers Conference
3. VIVUS to Participate in Three Investor Conferences in September
4. VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients
5. VIVUS Reports First Quarter 2011 Financial Results
6. VIVUS to Present at Four Upcoming Investor Conferences in May
7. VIVUS to Present at the 10th Annual Needham Healthcare Conference
8. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
9. VIVUS to Present at Four Upcoming Investor Conferences
10. VIVUS to Present at Two Upcoming Investor Conferences
11. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 PuraMed ... developer, and marketer of over-the-counter (OTC) medicinal and ... research opinion on the company based on low ... , Non-Prescription, All Natural Product to Treat ... Product Outperforms #1 Prescription Competitor , Currently ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 PI’s ... wide and provide 15 mm travel range with ... The small dimensions make these new positioners the ... spaces. A vacuum rated version is also available. ... specifications and datasheets can be found at: , ...
(Date:5/23/2013)... 23, 2013 Virobay, Inc. today announced that ... reached an important milestone, as Virobay has now initiated ... selective cathepsin S inhibitor.   The first ... placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics ... adults. "The initiation of this Phase 1 ...
(Date:5/23/2013)... Z Trim Holdings, Inc. (OTC Markets: ZTHO), ... of industries, announced that Chef Erin Ryan ... year,s National Restaurant Association ("NRA") NRA Show, which was ... Research Chefs Association.  Chef Ryan spoke on the subject ... and the Ugly," joining four other prestigious panelists including: ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3
... Fla., July 2 Bioheart, Inc. (Nasdaq:,BHRT) a ... of,autologous (patient-derived) cell therapies and devices for the ... it has been added to the,Russell Microcap Index ... of U.S. and global equity indexes on June ...
... Pharma, a leading provider of,knowledge management solutions to ... that the Aureus Pharma 2008 User Symposium will,be ... This symposium follows last year,s highly successful ... pharmaceutical and biotech customers,from both Europe and North ...
... 2 Research conducted at The,Walter and ... to a,major licensing agreement signed between Australian ... Merck,Serono., Under the Development and Licensing ... treatments for multiple sclerosis (MS) and other ...
Cached Biology Technology:Bioheart, Inc., Added to Russell Microcap Index 2Aureus Pharma Announces Date of 2008 Annual User Symposium 2MS Drug Development Agreement Based on WEHI's Medicinal Chemistry 2
(Date:5/23/2013)... fastest growing open-access publishers, announces the launch of ... Biotechnology . , A broad scope journal ... Biotechnology will provide a single open-access platform ... to be disseminated and discussed. , ... an open-science and interactive web platform for the ...
(Date:5/23/2013)... an age when microbial pathogens are growing increasingly resistant ... a team of Wisconsin scientists has synthesized a potent ... that cause staph infections. , Writing online in the ... group led by University of Wisconsin-Madison chemistry Professor Helen ... sensing" behavior of Staphylococcus aureus , a bacterium ...
(Date:5/22/2013)... Lung Screening Trial (NLST) investigators also conclude that ... with low-dose computed tomography (LDCT) versus chest X-ray ... paper is achievable at experienced screening centers in ... information to share with their patients about the ... following today,s publication in the New England ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in Bioengineering and Biotechnology 2University of Wisconsin chemists find new compounds to curb staph infection 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... DC Could some women who naturally produce excess ... developing breast cancer? Results of a new animal study ... Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown ... August 15 Cancer Research, the investigators say ...
... North American Societies provides a comprehensive and in-depth documentation ... adapting to the varied ecosystems of North America during ... of recurrent themes and questions that have shaped debates ... impact on their local environments throughout the Holocene. ...
... (Vancouver August 11, 2011) Pregnant women taking prenatal ... new Vancouver-based study led by the Child & Family Research ... Canadian Journal of Public Health . The study ... reported taking supplements containing vitamin D, many were vitamin D ...
Cached Biology News:Higher estrogen production in the breast could confer greater cancer risk than thought 2Higher estrogen production in the breast could confer greater cancer risk than thought 3Pregnant women in Vancouver may not be getting enough vitamin D 2
... (RNase III) from E. coli is an ... to dsRNA fragments that have 2-base, 3'-overhangs. ... dsRNA fragments of 12-15 bp. RNase ... canonical ribonucleotides as well as DuraScript™ RNA, ...
Rabbit polyclonal to Peptide E ( Abpromise for all tested applications)....
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
...
Biology Products: